Moors & Cabot Inc. Has $25.04 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Moors & Cabot Inc. increased its stake in Eli Lilly by 4.5% in the fourth quarter, bringing its holdings to 23,303 shares valued at about $25.04 million. Eli Lilly is now the firm’s 11th largest position and makes up roughly 1.1% of its portfolio.
• Institutional ownership in Eli Lilly remains very high, with hedge funds and other institutions holding 82.53% of the stock. Several other firms also modestly increased their positions during the period.
• Eli Lilly shares were trading near record highs and the company continues to post strong fundamentals, including a recent quarter with EPS of $8.55 and revenue of $19.80 billion, both above estimates. Analysts remain broadly bullish, with a consensus rating of Moderate Buy and an average price target of $1,227.

Moors & Cabot Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,303 shares of the company's stock after acquiring an additional 1,008 shares during the quarter. Eli Lilly and Company accounts for about 1.1% of Moors & Cabot Inc.'s holdings, making the stock its 11th largest position. Moors & Cabot Inc.'s holdings in Eli Lilly and Company were worth $25,043,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. 10Elms LLP lifted its holdings in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. grew its holdings in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after buying an additional 10 shares in the last quarter. Tanager Wealth Management LLP raised its position in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after buying an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC lifted its stake in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after acquiring an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC lifted its stake in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after acquiring an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 4.0%

LLY stock opened at $1,126.66 on Friday. The firm has a market cap of $1.06 trillion, a PE ratio of 40.02, a PEG ratio of 1.18 and a beta of 0.48. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,149.10. The company has a fifty day simple moving average of $952.15 and a 200 day simple moving average of $1,009.10. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company earned $3.34 earnings per share. The business's revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is 24.58%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LLY shares. Morgan Stanley reiterated an "overweight" rating and issued a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a research report on Tuesday. Guggenheim reiterated a "buy" rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Weiss Ratings lowered shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b-)" rating in a research note on Tuesday, May 19th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,227.00.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark will restore coverage for Zepbound and begin covering Lilly’s new obesity pill Foundayo, meaning all three major U.S. pharmacy benefit managers now cover Lilly’s full obesity portfolio. That broadens access, supports prescription growth, and strengthens Lilly’s position in the fast-growing weight-loss market. Article Title
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion combined, signaling a strategic expansion beyond obesity and diabetes into infectious disease prevention. Investors may view the deal-making as a long-term growth move that diversifies the pipeline. Article Title
• Positive Sentiment: The company also highlighted strong clinical momentum, including new data for Foundayo, Mounjaro, and retatrutide ahead of the ADA conference. The late-stage results suggest Lilly could keep extending its lead in cardiometabolic care. Article Title
• Positive Sentiment: Several firms reiterated bullish views, including BofA raising its price target and Wolfe Research maintaining an Outperform rating. That reinforces the market’s confidence in Lilly’s earnings and pipeline growth. Article Title
• Neutral Sentiment: Lilly presented at Bernstein’s Strategic Decisions Conference and is set to appear at other healthcare conferences, which keeps attention on management’s outlook but is not, by itself, a major fundamental driver. Article Title
• Negative Sentiment: Some commentary warned that Lilly’s valuation is rich and that Novo Nordisk could still be a strong competitor in the obesity-pill market. That may limit upside if investors become more cautious about how much growth is already priced in. Article Title

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.